DIAGNAMED HOLDINGS CORP.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE- AND NINE-MONTH PERIODS ENDED JUNE 30, 2025 AND 2024

(EXPRESSED IN CANADIAN DOLLARS)

(UNAUDITED)

Notice to Reader

Under National instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements have been prepared by and are the responsibility of management.

The Company's independent auditor has not performed a review of these condensed interim financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of the condensed interim financial statements by an entity's auditor.

DiagnaMed Holdings Corp.

Condensed Interim Consolidated Statements of Financial Position
(Stated in Canadian Dollars)
(Unaudited)

	Notes	June 30, 2025	September 30, 2024
ASSETS			
Current assets			
Cash and cash equivalents		$ 261,464	$ 162,146
Amounts receivable		26,642	32,099
Prepaid expenses		-	7,500
TOTAL ASSETS		$ 288,106	$ 209,245
LIABILITIES AND EQUITY			
Current liabilities			
Trade and other payables		$ 385,999	$ 466,912
Total liabilities		385,999	466,912
Shareholders' equity (deficit)			
Common shares	**3**	4,512,535	3,568,686
Share-based payments reserve	**4**	1,188,134	1,025,389
Deficit		(5,798,562)	(4,859,242)
Total equity		(97,893)	(265,167)
TOTAL LIABILITIES AND EQUITY		$ 288,106	$ 201,745
Nature of operations and going concern	**1**		
Subsequent event	**11**		

Approved on behalf of the Board of Directors:

"Ming Jang"
Ming Jang, Director

"Fabio Chianelli"
Fabio Chianelli, Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

DiagnaMed Holdings Corp.

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Stated in Canadian Dollars)

(Unaudited)

	Notes	Three-months ended June 30, 2025	Three-months ended June 30, 2024	Nine-months ended June 30, 2025	Nine-months ended June 30, 2024
Expenses					
Consulting fees	**7**	$ 143,429	$ 45,000	$ 152,000	$ 141,875
Exploration and evaluation expenditures	**3**	437,500	-	437,500	-
General and administrative		7,841	13,981	17,713	70,181
Investor relations		11,021	10,796	66,739	35,288
Professional fees		8,648	19,374	58,365	82,167
Research and development		25,000	77,888	146,267	263,244
Share-base payments	**4**	30,080	-	133,545	-
Foreign exchange		(19,568)	2,133	4,020	(33,397)
Loss before other items		(643,951)	(169,172)	(1,016,149)	(559,358)
Other income (expense)					
Interest income (expense)		487	(51,450)	1,829	2,239
Gain on settlement of debt	**7**	75,000	-	75,000	249,741
Loss and comprehensive loss for the period		$ (568,464)	$ (220,622)	$ (939,320)	$ (307,378)
Weighted average number of common shares outstanding					
Basic		99,315,526	80,052,640	88,649,495	80,052,640
Diluted		99,315,526	80,052,640	88,649,495	80,052,640
Basic and diluted loss per common share		$ 0.00	$ (0.00)	$ (0.01)	$ (0.00)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

DiagnaMed Holdings Corp.

Condensed Interim Consolidated Statements of Changes in Shareholders' Deficit

(Stated in Canadian Dollars)

(Unaudited)

	Common Shares		Share-based Payments		
	Number	Amount	Reserve	Deficit	Total
Balance at September 30, 2024	80,052,640	$ 3,568,686	$ 1,025,389	$ (4,859,242)	$ (265,167)
Common shares issued for debt settlement	1,356,000	67,800	-	-	67,800
Common shares issued for services	2,000,000	100,000	-	-	100,000
Common shares issued for exploration and evaluation properties	12,500,000	437,500	-	-	437,500
Common shares issued for cash:					
Private placement	13,250,333	397,510	-	-	397,510
Share issue costs	-	(58,961)	29,200	-	(29,761)
Share-based payments	-	-	133,545	-	133,545
Loss and comprehensive loss for the period	-	-	-	(939,320)	(939,320)
Balance at June 30, 2025	109,158,973	$ 4,512,535	$ 1,188,134	$ (5,798,562)	$ (97,893)

	Common Shares		Share-based Payments		
	Number	Amount	Reserve	Deficit	Total
Balance at September 30, 2023	80,052,640	$ 3,568,686	$ 1,025,389	$ (4,358,185)	$ 235,890
Loss and comprehensive loss for the period	-	-	-	(307,378)	(307,378)
Balance at June 30, 2024	80,052,640	$ 3,568,686	$ 1,025,389	$ (4,665,563)	$ (71,488)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

DiagnaMed Holdings Corp.

Condensed Interim Consolidated Statements of Cash Flows

(Stated in Canadian Dollars)

(Unaudited)

	Nine-months ended June 30, 2025	Nine-months ended June 30, 2024
Operating activities		
Loss for the period	$ (939,320)	$ (307,378)
Items not involving cash:		
Shares issued for services	100,000	-
Shares issued for settlement of debt	67,800	-
Shares issued for exploration and evaluation properties	437,500	-
Share-based payments	133,545	-
Gain on settlement of debt	(75,000)	(249,741)
Changes in non-cash working capital items:		
Amounts receivable	5,457	25,690
Prepaid expenses	7,500	-
Trade and other payables	(5,913)	96,968
Net cash used in operating activities	(268,431)	(434,461)
Financing activity		
Proceeds from issuance of common shares, net of issue costs	367,749	-
Net cash provided by financing activity	367,749	-
Change in cash during the period	99,318	(434,461)
Cash and cash equivalents, beginning of the period	162,146	606,963
Cash and cash equivalents, end of the period	$ 261,464	$ 172,502
Cash and cash equivalents consists of:		
Cash	$ 261,464	$ 83,416
Cash equivalents	-	-
	$ 261,464	$ 83,416
Supplemental Cash Flow Information		
Income taxes paid	$ -	$ -
Interest paid (received)	$ -	$ -
Non-cash Financing Activities		
Fair value of finder warrants issued	$ 29,200	$ -

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

1. NATURE OF OPERATIONS AND GOING CONCERN

Diagnamed Holdings Corp. ("Diagnamed" or the "Company) was incorporated under the Business Corporations Act (British Columbia) on April 16, 2021. On November 8, 2022, the Company's common shares were approved for listing on the Canadian Securities Exchange (the "CSE") and commenced trading under the trading symbol "DMED". The registered head office of the Company is 82 Richmond Street East, Toronto, ON. M5C 1P1, Canada.

These unaudited condensed interim consolidated financial statements have been prepared using accounting policies in compliance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) on the assumption that the Company will continue as a going concern and realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation.

The Company’s principal business activities include the delivery of innovative technology solutions for the cleantech and life sciences industries, with a focus on hydrogen production and AI-driven drug discovery and diagnostics. Currently, the Company is focused on the commercialization of two technologies: (1) a proprietary electromagnetic heating technology enabling hydrogen production from petroleum reservoirs and natural hydrogen fields, and (2) BRAIN AGE® BRAIN HEALTH, a proprietary brain health AI platform for the healthcare market.

As at June 30, 2025, the Company had not yet achieved profitable operations, had an accumulated deficit of $5.798,562 since inception, and expects to incur further losses in the development of its business. These events and conditions indicate a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is primarily dependent upon its ability to raise financing from equity markets or borrowings and, upon successful results from its business activities. While the Company has been successful in securing financings in the past, there is no assurance that it will be able to do so in the future. Accordingly, these financial statements do not give effect to adjustments, if any, that would be necessary should the Company be unable to continue as a going concern. If the going concern assumption was not used, then the adjustments required to report the Company’s assets and liabilities on a liquidation basis could be material to these financial statements.

2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES

a) Statement of compliance

These condensed interim consolidated financial statements, including comparatives, are unaudited and have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting (“IAS 34”) using accounting policies consistent with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”) and Interpretations of the IFRS Interpretations Committee (“IFRIC”).

b) Basis of presentation

These financial statements were presented in Canadian dollars and all values are rounded to the nearest dollar except where otherwise indicated. The financial statements have been prepared on an accrual basis, except for the statements of cash flows, and are based on historical costs.

2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES

c) Approval of the financial statements

The financial statements of the Company for the nine-month period ended June 30, 2025 were reviewed, approved and authorized for issue by the Board of Directors on August 14, 2025.

d) New standards, interpretations and amendments not yet adopted

Certain pronouncements were issued by the IASB or the Interpretations of the IFRS Interpretations Committee that are mandatory for accounting periods on or after October 1, 2024 or later periods. Many are not applicable or do not have a significant impact to the Company and have been excluded. The following has not yet been adopted and is being evaluated to determine their impact on the Company.

IFRS 10 – Consolidated Financial Statements ("IFRS 10") and IAS 28 – Investments in Associates and Joint Ventures("IAS 28") were amended in September 2014 to address a conflict between the requirements of IAS 28 and IFRS 10 and clarify that in a transaction involving an associate or joint venture, the extent of gain or loss recognition depends on whether the assets sold or contributed constitute a business. The effective date of these amendments is yet to be determined, however early adoption is permitted.

3. SHARE CAPITAL

a) Authorized:

An unlimited number of common shares with no par value.

b) During the nine-month period ended June 30, 2025, the Company issued the following common shares:

- The Company issued 1,356,000 shares in settlement of accounts payable of $67,800.

- On January 14, 2025, the Company issued 2,000,000 shares to Quebec Innovative Materials Corp. ("QIMC") at a deemed price of $0.05 per share for a total of $100,000 research expense (see Note 8) based on the collaboration agreement signed between QIMC and the Company. The Company and QIMC have common directors and officers.

- On April 11, 2025, the Company closed its private placement by issuing 13,250,333 units of the Company at an issue price of $0.03 per unit for aggregate gross proceeds of $397,510. Each unit consists of one common share in the capital of the company and one common share purchase warrant, with each warrant entitling the holder to acquire one additional common share for a period of 24 months from closing at an exercise price of $0.05.

  In connection with the closing of the offering, the Company paid finders' fees in the aggregate amount of $29,761 and issued 992,027 finder warrants. Each finder warrant entitles the holder to acquire one additional common share for a period of 24 months from closing at an exercise price of $0.05 per warrant.

3. SHARE CAPITAL (continued):

The Company also issued 992,027 finder warrants to arm's length third parties. Each finder warrant entitles the holder to acquire one common share of the Company for the price of $0.05 per common share for a period of two years following the closing.

The fair value of the broker warrants was estimated using the Black-Scholes option pricing model assuming a risk-free interest rate of 2.68%, a dividend yield of nil, a weighted average expected annual volatility of the Company's share price of 346% and an expected life of 2 years. The fair value of the broker warrants was $0.03 per warrant. The expected volatility assumption is based on the estimated volatility of comparable early-stage mineral exploration companies. The risk-free interest rate is based on yield curves on the Canadian government zero-coupon bonds or Canadian government treasury bills with a remaining term equal to the warrant's expected life.

- On May 30, 2025, the Company issued 12,500,000 for the acquisition of 91 unpatented, single-cell mineral claims, each cell approximately 20 hectares in size, totaling an area of 1,820 hectares, within Ontario's highly prospective Temiscamingue hydrogen district and graben. Under the terms of the acquisition agreement, the Company is also required to make a non-refundable $25,000 payment. The Company has also granted certain sellers a 2.0-per-cent royalty on revenues from the sale of any hydrogen or other minerals on the property. Fifty per cent of the seller royalty may be purchased for $2 million.

During the nine-month period ended June 30, 2024, there were no common shares issued by the Company.

4. SHARE-BASED PAYMENTS RESERVE

a) Warrants

The changes in warrants during the nine-month periods June 30, 2025 and 2024 are as follows:

	Nine-month periods ended June 30,					
	2025			2024		
	Number of warrants		Weighted-average exercise price	Number of warrants		Weighted-average exercise price
Balance beginning of period	-	$	-	-	$	-
Issued	14,242,360		0.05	-		-
Balance, June 30,	14,242,360	$	0.05	-	$	-

Warrants exercisable and outstanding as at June 30, 2025 are as follows:

Expiry Date	Number of warrants		Exercise Price
April 11, 2027	14,242,360	$	0.05

4. SHARE-BASED PAYMENTS RESERVE (continued):

b) Stock Options:

The Company has adopted an incentive stock option plan in accordance with the policies of the Exchange (the "Stock Option Plan"). Options may be granted for a maximum term of five years from the date of the grant. They are not transferable. Unless the Board determines otherwise, options shall be exercisable in whole or in part at any time during this period. Options expire within 90 days of termination of employment or holding office as director or officer of the Company and, in the case of death, expire within a maximum period of one year after such death, subject to the expiry date of the option.

During the nine-month period ended June 30, 2025, the Company granted the following stock options:

- On November 11, 2024, the Company granted 4,500,000 stock options to certain Directors, Officers, and Consultants of the Company with each stock option exercisable into one common share of the Company at an exercise price of $0.05 per share for five years from the date of grant and vest immediately. The options will vest 25% every three months from the date of grant.

  The options were valued at $130,690 using a Black-Scholes valuation model with the following assumptions: share price of $0.04 per common shares, expected dividend yield of 0%, expected volatility of 100%, risk-free rate of 3.02%, and expected life of 5 years.

- On January 8, 2025, the Company granted 1,000,000 stock options to certain consultants of the Company with each stock option exercisable into one common share of the Company at an exercise price of $0.05 per share for five years from the date of grant. The options will vest 25% every three months from the date of grant.

  The options were valued at $33,402 using a Black-Scholes valuation model with the following assumptions: share price of $0.05 per common shares, expected dividend yield of 0%, expected volatility of 100%, risk-free rate of 3.02%, and expected life of 5 years.

During the nine-month period ended June 30, 2024, there were no stock options granted by the Company.

The changes in stock options outstanding during the nine-month periods ended June 30, 2025 and 2024 are as follows:

	Nine-month periods ended June 30,					
	2025			2024		
	Number of options		Weighted-average exercise price	Number of options		Weighted-average exercise price
Balance beginning of period	1,750,000	$	0.10	1,750,000	$	0.10
Granted	5,500,000		0.05	-		-
Cancelled	(4,050,000)		0.07	-		-
Balance, June 30,	3,200,000	$	0.05	1,750,000	$	0.10

4. SHARE-BASED PAYMENTS RESERVE (continued):

Stock options exercisable and outstanding as at June 30, 2025 are as follows:

Expiry Date	Number of options		Exercise Price
January 4, 2027	200,000	$	0.10
November 11, 2029	3,000,000		0.05
	3,200,000	$	0.05[1]

[1]Weighted-average exercise price.

5. FINANCIAL INSTRUMENTS

Fair value estimates are made at the statement of financial position date, based on relevant market information and other information about financial instruments. As at June 30, 2025 and 2024, the Company's financial instruments are cash and cash equivalents and trade and other payables. The amounts reflected in the statement of financial position approximate their fair values due to the short-term nature of these financial instruments.

The Company is exposed to various financial risks resulting from both its operations and its investment activities. The Company's management manages financial risks. The Company does not enter into financial instruments agreements, including derivative financial instruments for speculative purposes. There have been no changes in the Company's management and exposure of risks associated with financial instruments during the three-month periods ended June 30, 2025 and 2024.

The Company's financial risks exposure and its financial policies are as follows:

a) Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company's cash and cash equivalents are exposed to credit risk, with the carrying value being the Company's maximum exposure. The Company's cash and cash equivalents consists of funds held at Canadian chartered banks or occasionally, in trust with the Company's corporate lawyer. Management does not believe the Company is exposed to material credit risk.

b) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due.

As at June 30, 2025, the Company had a cash and cash equivalents balance of $261,464 to settle trade and other payables of $385,999. All of the Company's trade and other payables have contractual maturities of 30 days or are due on demand and are subject to normal trade terms. The Company expects to fund future expenditures through the issuance of capital stock.

5. FINANCIAL INSTRUMENTS (continued):

c) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk. Management does not believe the Company is exposed to material currency or other price risk.

d) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk as cash and cash equivalents comprise $261,464 held at Canadian chartered banks

The Company had no interest rate swaps or financial contracts in place as at or during the nine-month periods ended June 30, 2025 and 2024.

6. CAPITAL MANAGEMENT

The Company's capital currently consists of common shares in the amount of $4,512,535 (2024 - $3,568,686) and its principal source of cash is from the issuance of common shares. The Company's capital management objectives are to safeguard its ability to continue as a going concern and to have sufficient capital to be able to acquire and develop its business interests. The Company does not have any externally imposed capital requirements to which it is subject. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new equity instruments.

The Company is dependent on external financing to fund its activities. In order to carry out its operations, the Company will spend its existing working capital and raise additional amounts as needed.

There were no changes in the Company's approach to capital management during the nine-months periods ended June 30, 2025 and 2024.

7. RELATED PARTY TRANSACTIONS

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence, related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

7. RELATED PARTY TRANSACTIONS (continued):

The following is a summary of the related party transactions that occurred during the three-month periods ended June 30, 2025 and 2024.

a) Compensation of key management personnel

The Company has determined that key management personnel consist of its Directors, the CEO and, the CFO.

	Three-month periods ended June 30,		Nine-month periods ended June 30,	
	2025	2024	2025	2024
Management fees paid or accrued to a company controlled by the former CEO of the Company	$ 15,000	$ 45,000	$ 105,000	$ 135,000
Management fees paid or accrued to a company controlled by the CEO of the Company	4,179	-	4,179	-
Consulting fees paid or accrued to a company controlled a director of the Company	3,250	-	3,250	-
Management fees paid or accrued to a company that employed the CFO of the Company	10,664	10,640	40,078	38,662
Share-based payments	17,653	-	70,266	-
Total	$ 50,746	$ 55,640	$ 222,773	$ 173,662

During the nine-month period ended June 30, 2025, the former CEO of the Company forgave $75,000 in management fees owing.

On January 14, 2025, the Company issued 2,000,000 shares to Quebec Innovative Materials Corp. ("QIMC") at a deemed price of $0.05 per share for a total of $100,000 research expense (see Note 8) based on the collaboration agreement signed between QIMC and the Company. The Company and QIMC have common directors and officers.

On May 28, 2025, the Company entered into an Acquisition Agreement to acquire issued 91 unpatented, single-cell mineral claims, each cell approximately 20 hectares in size, totaling an area of 1,820 hectares, within Ontario's highly prospective Temiscamingue hydrogen district and graben. Under the terms of the acquisition agreement, the Company is also required to issue 12,500,000 shares of the Company and make a non-refundable $25,000 payment. In addition, the Company has granted certain sellers a 2.0-per-cent royalty on revenues from the sale of any hydrogen or other minerals on the property. Fifty per cent of the seller royalty may be purchased for $2 million. The sellers of the properties includes an officer of the Company and as such, the transaction is determined to be a related party transaction.

8. RESEARCH

Hydrogen

DiagnaMed's cutting-edge hydrogen production technology represents a breakthrough in clean energy. Developed by Dr. Qingwang Yuan of the at Texas Tech University, the patented method combines hydraulic fracturing with electromagnetic wave heating to extract hydrogen from light oil, gas, and shale reservoirs, as well as ultramafic rock formations.

This technology offers efficiency and sustainability with potential hydrogen production costs as low as $0.86 per kilogram. The method aligns with the U.S. Department of Energy's "Hydrogen Energy Earthshot" initiative to achieve $1 per kilogram hydrogen production by 2031.

BrainTremor™

DiagnaMed is investigating technological applications that monitor, collect and use individual information to detect tremors, and measuring cognitive and brain activity in patients with neurological disorders.

BRAIN AGE® Brain Health

BRAIN AGE® Brain Health is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders.

9. COMMITMENTS

On June 24, 2021, the Company has entered into a licensing arrangement with the Drexel University relating to the BrainAge™ project, whereby US$2,500 will be paid each year and certain milestone payments and royalties are payable upon the achievement of certain events. The Company will record these amounts as the events occur.

On December 8, 2021, the Company entered into a licensing agreement with the University of Colorado relating to certain patents held by the University of Colorado for self-healable, recyclable, reconfigurable and wearable electronics devices. The Company is committed to pay to University of Colorado license fees of US$10,000 on December 8, 2021 (the "Effective Date") and license maintenance fees as follows: US$10,000 on the third anniversary of the Effective Date, US$15,000 on the fourth anniversary of the Effective Date, US$30,000 on the fifth anniversary of the Effective Date, US$50,000 on the sixth anniversary of the Effective Date and $US75,000 on the seventh and subsequent anniversaries of the Effective Date until the termination of the agreement. On April 11, 2023, the license agreement was terminated and there are no further obligations.

On November 15, 2022, the Company announced it entered into a license agreement with KU Center for Technology Commercialization, Inc. ("KUTC"), a non-profit corporation of the University of Kansas, for the development and commercialization of intellectual property of a novel virtual reality and artificial intelligence neurodiagnostic system ("VR/AI Neuro") for the evaluation, diagnosis and monitoring of neurodegenerative diseases, such as Parkinson's disease. The Company paid to KUTC a one-time license fee of US$6,000 and committed to pay annual license maintenance fees of US$2,000. On July 10, 2023, the license was terminated and there are no further obligations.

9. COMMITMENTS (continued):

On February 22, 2023, the Company announced it entered into a license agreement with the University of Miami ("UM") for the development and commercialization of intellectual property of a novel brain health platform for the evaluation, diagnosis and monitoring of brain health, such as Alzheimer's disease and related dementias, which will be incorporated with BRAIN AGE® Brain Health. The Company paid to UM a one-time license fee of US$15,000 and committed to pay license maintenance fees of US$10,000 on the third and each subsequent anniversary.

10. COMPARATIVE FIGURES

Certain comparative figures have been reclassified to conform with the current year presentation. Such reclassification had no impact on

11. SUBSEQUENT EVENT

Subsequent to the period ended June 30, 2025, the Company granted an aggregate of 5,475,000 stock options to certain Directors, Officers, and Consultants of the Company with each stock option exercisable into one common share of the Company at an exercise price of $0.05 per share for three years.